ELUT (Elutia) Operating Cash Flow per Share : $-0.83 (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Elutia Operating Cash Flow per Share?

Elutia's operating cash flow per share for the three months ended in Mar. 2025 was $-0.21. Elutia's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.83.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 19.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 15.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Elutia's Operating Cash Flow per Share or its related term are showing as below:

ELUT' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -19.7 Med: 3.5 Max: 36.9
Current: 19.2

During the past 7 years, Elutia's highest 3-Year average Operating Cash Flow per Share Growth Rate was 36.90% per year. The lowest was -19.70% per year. And the median was 3.50% per year.

ELUT's 3-Year OCF Growth Rate is ranked better than
65.42% of 697 companies
in the Medical Devices & Instruments industry
Industry Median: 8.2 vs ELUT: 19.20

Elutia Operating Cash Flow per Share Historical Data

The historical data trend for Elutia's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elutia Operating Cash Flow per Share Chart

Elutia Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-4.78

-1.48

-1.55

-1.20

-0.78

Elutia Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.11	-0.17	-0.10	-0.35	-0.21

Competitive Comparison of Elutia's Operating Cash Flow per Share

For the Medical Devices subindustry, Elutia's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elutia's Price-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Elutia's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Elutia's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Elutia Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Elutia's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-22.657	/	29.071
	=	-0.78

Elutia's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	-8.881	/	42.913
	=	-0.21

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.83

Elutia Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Elutia's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Elutia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elutia Inc (NAS:ELUT) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

12510 Prosperity Drive, Suite 370, Silver Spring, MD, USA, 20904

Website

https://www.aziyo.com

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Executives

Highcape Capital, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Elutia Pipe Investment, Lp	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Birchview Fund Llc	10 percent owner	688 PINE STREET, BURLINGTON VT 05401
Thomas Englese	officer: Chief Commercial Officer	C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRING MD 20904
David Colpman	director	452 FIFTH AVENUE, NEW YORK NY 10018
Brigid Makes	director	20245 SW 95TH AVENUE, TUALATIN OR 97062
Matthew Ferguson	officer: Chief Financial Officer	C/O FOXHOLLOW TECHNOLOGIES, INC., 740 BAY ROAD, REDWOOD CITY CA 94063
Highcape Partners Gp Ii, Llc	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Gp Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Qp Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Michelle Leroux Williams	officer: Chief Scientific Officer	C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRINT MD 20904
Matthew Strobeck	10 percent owner	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Birchview Capital, Lp	10 percent owner	688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON VT 05401
Peter G Edwards	officer: GENERAL COUNSEL	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015